Immunomedics and Everest Medicines announced an exclusive license agreement to develop, register and commercialize sacituzumab govitecan in Greater China, South Korea and certain Southeast Asian countries. Immunomedics will receive an upfront payment of $65M and an additional $60M based on FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer. Everest will develop and commercialize the product in various global and local indications across the territory. The company is eligible to receive development and sales milestone payments of up to $710M, as well as escalating tiered royalties that begin in the mid-teens based on net sales within the territory. Pursuant to the agreement, Everest Medicines will be responsible for all costs associated with the clinical development and commercialization of sacituzumab govitecan in the territory, while a joint steering committee will be established between the companies to oversee the overall strategy and priorities.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.